Εμφάνιση απλής εγγραφής

dc.creatorKotsiou O.S., Gourgoulianis K.I., Zarogiannis S.G.en
dc.date.accessioned2023-01-31T08:44:47Z
dc.date.available2023-01-31T08:44:47Z
dc.date.issued2021
dc.identifier10.1016/j.rmed.2021.106350
dc.identifier.issn09546111
dc.identifier.urihttp://hdl.handle.net/11615/75214
dc.description.abstractNitric oxide (NO) regulates various physiological and pathophysiological functions in the lungs. However, there is much less information about the effects of NO in the pleura. The present review aimed to explore the available evidence regarding the role of NO in pleural disease. NO, has a double-edged role in the pleural cavity. It is an essential signaling molecule mediating various physiological cell functions such as lymphatic drainage of the serous cavities, the immune response to intracellular multiplication of pathogens, and downregulation of neutrophil migration, but also induces genocytotoxic and mutagenic effects when present in excess. NO is implicated in the pathogenesis of asbestos-related or exudative pleural disease and mesothelioma. From a clinical point of view, the fraction of exhaled NO has been suggested as a potential non-invasive tool for the diagnosis of benign asbestos-related disorders. Under experimental conditions, NO-mimetics were found to attenuate hypoxia-induced therapy resistance in mesothelioma. Similarly, hybrid agents consisting of an NO donor coupled with a parent anti-inflammatory drug showed an enhancement of the anti-inflammatory activity of anti-inflammatory drugs. However, given the paucity of research work performed over the last years in this area, further research should be undertaken to establish reliable conclusions with respect to the feasibility of determining or targeting the NO signaling pathway for pleural disease diagnosis and therapeutic management. © 2021 Elsevier Ltden
dc.language.isoenen
dc.sourceRespiratory Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85101681993&doi=10.1016%2fj.rmed.2021.106350&partnerID=40&md5=41a9441f107179bd84a5458a25d88931
dc.subjectasbestosen
dc.subjectnitric oxideen
dc.subjectnitric oxide donoren
dc.subjectnonsteroid antiinflammatory agenten
dc.subjectantiinflammatory agenten
dc.subjectasbestosen
dc.subjectbiological markeren
dc.subjectnitric oxideen
dc.subjectnitric oxide donoren
dc.subjectdown regulationen
dc.subjectfractional exhaled nitric oxideen
dc.subjecthumanen
dc.subjecthypoxiaen
dc.subjectimmune responseen
dc.subjectlung diseaseen
dc.subjectlung functionen
dc.subjectlymphatic drainageen
dc.subjectmalignant pleura effusionen
dc.subjectmesotheliomaen
dc.subjectneutrophilen
dc.subjectpathogenesisen
dc.subjectpathophysiologyen
dc.subjectpleura cavityen
dc.subjectpleura diseaseen
dc.subjectpleura effusionen
dc.subjectpleura plaqueen
dc.subjectpleurisyen
dc.subjectpriority journalen
dc.subjectReviewen
dc.subjectsignal transductionen
dc.subjectmesotheliomaen
dc.subjectmetabolismen
dc.subjectphysiologyen
dc.subjectpleuraen
dc.subjectpleura diseaseen
dc.subjectAnti-Inflammatory Agentsen
dc.subjectAsbestosen
dc.subjectBiomarkersen
dc.subjectHumansen
dc.subjectMesotheliomaen
dc.subjectNitric Oxideen
dc.subjectNitric Oxide Donorsen
dc.subjectPleuraen
dc.subjectPleural Diseasesen
dc.subjectSignal Transductionen
dc.subjectW.B. Saunders Ltden
dc.titleThe role of nitric oxide in pleural diseaseen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής